Steroid receptors and their role in the biology and control of breast cancer growth

被引：74

作者：

Cordera, Fernando ^{[1
]}

Jordan, V. Craig ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

来源：

SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 06期

关键词：

D O I：

10.1053/j.seminoncol.2006.08.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Steroid hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) play a critical role in the development of breast cancer. Most importantly, the expression of ER and/or PR by tumor cells provides important information that is critical for the selection of treatment. Recent studies on ER and PR have provided new insights into the pathogenesis of breast cancer and the mechanisms of resistance to antihormonal therapy. Better understanding of steroid receptors, their ligands, and the mechanisms through which they exert their effects will allow the correct treatment to be targeted to responsive tumors. © 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：631 / 641

页数：11

相关论文

共 107 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database [J].

Anderson, WF ;

Chu, KC ;

Chatterjee, N ;

Brawley, O ;

Brinton, LA .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :18-27

[3]

Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance [J].

Arpino, G ;

Weiss, H ;

Lee, AV ;

Schiff, R ;

De Placido, S ;

Osborne, CK ;

Elledge, RM .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1254-1261

[4]

Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women [J].

Balleine, RL ;

Earl, MJ ;

Greenberg, ML ;

Clarke, CL .

BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1564-1571

[5]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[6]

Long-term exposure to tamoxifen induces hypersensitivity to estradiol [J].

Berstein, LM ;

Wang, JP ;

Zheng, H ;

Yue, W ;

Conaway, M ;

Santen, RJ .

CLINICAL CANCER RESEARCH, 2004, 10 (04) :1530-1534

[7]

Quantification of estrogen receptor α and β expression in sporadic breast cancer [J].

Bièche, I ;

Parfait, B ;

Laurendeau, I ;

Girault, I ;

Vidaud, M ;

Lidereau, R .

ONCOGENE, 2001, 20 (56) :8109-8115

[8]

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial [J].

Boccardo, F ;

Rubagotti, A ;

Puntoni, M ;

Guglielmini, P ;

Amoroso, D ;

Fini, A ;

Paladini, G ;

Mesiti, M ;

Romeo, D ;

Rinaldini, M ;

Scali, S ;

Porpiglia, M ;

Benedetto, C ;

Restuccia, N ;

Buzzi, F ;

Franchi, R ;

Massidda, B ;

Distante, V ;

Amadori, D ;

Sismondi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5138-5147

[9]

Induction of mammary gland development in estrogen receptor-α knockout mice [J].

Bocchinfuso, WP ;

Lindzey, JK ;

Hewitt, SC ;

Clark, JA ;

Myers, PH ;

Cooper, R ;

Korach, KS .

ENDOCRINOLOGY, 2000, 141 (08) :2982-2994

[10]

FDA drug approval summaries: Fulvestrant [J].

Bross, PF ;

Cohen, MH ;

Williams, GA ;

Pazdur, R .

ONCOLOGIST, 2002, 7 (06) :477-480

← 1 2 3 4 5 6 7 8 9 10 →